About Us
We are a preclinical stage bio-pharmaceutical company located in Paris
We are mission-driven, dedicated to advancing medicine, improving patients’ health and saving lives
We have the ambition to become a leading player in the market of rare kidney diseases in both adults and children
We are first focused on the treatment of Crescentic Glomerulonephritis in adults, a severe condition with no effective treatment
The company is lead by a seasoned and complementary leadership team with more than 130 years of experience in successfully bringing products on the market.
Backed by renowed clinical leaders in renal medicine and a large access to patients network, DETERA Therapeutics is well-positioned to advance its mission.
Lyse SANTORO- PhD & Insead
Co-Founder & CEO
The Executive Team
Daniel GILLET- PhD
Co-Founder & CSO/COO
Pierre-Louis THARAUX- MD, PhD
Co-Founder & CMO
André ULMANN- MD, PhD
Business Angel, Successful Serial Entrepreneur
Founders & Sharesholders
Our Key Opinion Leaders
Pr David Jayne
Cambridge University Hospitals, United Kingdom
Pr Tobias Huber
University Medical Center, Hambrug Center for Kidney Health, Hamburg, Germany
Pr Noémie Jourde-Chiche
Marseille Hospital (APHM), Marseille, France
Pr Eric Daugas
Bichat Claude-Bernard Hospital, Paris, France
Access to Patients
Pr Pierre-Louis Tharaux
Inserm Institute, Georges Pompidou Hospital, Paris, France
Pr Alexandre Karras
Nephrology service, Georges Pompidou Hospital, Paris, France
Benjamin Terrier
President of the Administration Committee, French Vasculitis Study Group (GFEV); Paris, France
Neeraj Dhaun
Queen’s Medical Research Institute, University of Edinburg, United Kingdom (cohort of patients with auto-immune nephropathies)